实现艾滋病治愈的进展：2014年国际艾滋病学会研讨会最新情况
Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium.
作者信息
Anderson Jenny Louise, Fromentin Rémi, Corbelli Giulio Maria, Østergaard Lars, Ross Anna Laura
机构信息
1 The Peter Doherty Institute, The University of Melbourne , Melbourne, Australia .
出版信息
AIDS Res Hum Retroviruses. 2015 Jan;31(1):36-44. doi: 10.1089/AID.2014.0236.
Abstract
Biomedical research has led to profound advances in the treatment of HIV infection. Combination antiretroviral therapy (ART) now provides the means to readily control viral infection, and people living with HIV who receive timely and effective ART can expect to benefit from a life expectancy comparable to uninfected individuals. Nevertheless, despite effective treatment, ART does not fully restore the immune system and importantly HIV persists indefinitely in latent reservoirs, resulting in the need for life-long treatment. The challenges and limits of life-long treatment have spurred significant scientific interest and global investment into research towards an HIV cure. The International AIDS Society (IAS) 2014 Towards an HIV cure symposium brought together researchers and community to discuss the most recent advances in our understanding of latency and HIV reservoirs, and the clinical approaches towards an HIV cure under current investigation. This report summarizes and reviews some of the major findings discussed during the symposium.
摘要
生物医学研究已在HIV感染治疗方面取得了深远进展。联合抗逆转录病毒疗法（ART）如今提供了轻松控制病毒感染的手段，接受及时有效ART治疗的HIV感染者有望获得与未感染者相当的预期寿命。然而，尽管治疗有效，但ART并不能完全恢复免疫系统，重要的是HIV会在潜伏库中无限期持续存在，这就导致需要终身治疗。终身治疗的挑战和局限激发了科学界的浓厚兴趣以及全球对治愈HIV研究的投资。国际艾滋病学会（IAS）2014年关于治愈HIV的研讨会汇聚了研究人员和社会各界，以讨论我们对潜伏期和HIV潜伏库理解的最新进展，以及目前正在研究的治愈HIV的临床方法。本报告总结并回顾了研讨会上讨论的一些主要发现。
相似文献
1
Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium.实现艾滋病治愈的进展：2014年国际艾滋病学会研讨会最新情况
AIDS Res Hum Retroviruses. 2015 Jan;31(1):36-44. doi: 10.1089/AID.2014.0236.
2
Reservoirs dog AIDS therapy.储存库对艾滋病治疗产生影响。
Nature. 2000 May 18;405(6784):270-2. doi: 10.1038/35012712.
3
Forcing the enemy to come out and surrender: a strategy for an AIDS cure.
AIDS Res Hum Retroviruses. 2015 Jan;31(1):45-6. doi: 10.1089/aid.2014.0259.
4
HIV/AIDS: waiting for a cure.
J Allergy Clin Immunol. 2008 Jul;122(1):34-5. doi: 10.1016/j.jaci.2008.05.029. Epub 2008 Jun 10.
5
The challenge of finding a cure for HIV infection.寻找治愈艾滋病毒感染方法的挑战。
Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706.
6
Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.热休克反应通过 p-TEFb 和 NF-κB 通路介导硫链丝菌素重新激活潜伏的 HIV-1。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02328-19.
7
Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.HIV-1 感染治疗研究的新进展：针对 HIV-1 潜伏库。
J Allergy Clin Immunol. 2014 Jul;134(1):12-9. doi: 10.1016/j.jaci.2014.05.026. Epub 2014 Jun 26.
8
Eradication of HIV-1 latent reservoirs through therapeutic vaccination.通过治疗性疫苗接种根除HIV-1潜伏库。
AIDS Res Ther. 2017 Sep 12;14(1):45. doi: 10.1186/s12981-017-0177-4.
9
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.HIV-1 潜伏库的生物学特性及其对治愈策略的影响。
Cell Host Microbe. 2020 Apr 8;27(4):519-530. doi: 10.1016/j.chom.2020.03.014.
10
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.马拉维若与潜伏 HIV-1 再激活有关，通过抑制性抗逆转录病毒治疗的 HIV 感染者静息 CD4 T 细胞中 NF-κB 的激活。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01931-17. Print 2018 May 1.
引用本文的文献
1
Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine.ICVAX-a 一种基于人 PD1 的双价 HIV-1 Gag-p41 嵌合 DNA 疫苗增强了交叉反应性和多功能效应记忆 T 细胞应答。
J Virol. 2022 Apr 13;96(7):e0216121. doi: 10.1128/jvi.02161-21. Epub 2022 Mar 17.
2
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response.参与治疗性疫苗试验的HIV-1感染患者的抗逆转录病毒治疗中断（ATI）：病毒学反应的替代标志物
Vaccines (Basel). 2020 Aug 5;8(3):442. doi: 10.3390/vaccines8030442.
3
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).HIVconsv 疫苗联合罗米地辛治疗早期 HIV-1 感染者：安全性、免疫原性和对病毒储存库的影响（BCN02 研究）。
Front Immunol. 2020 May 6;11:823. doi: 10.3389/fimmu.2020.00823. eCollection 2020.
4
Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients.慢性HIV-1感染患者分析性治疗中断期间的病毒学转归指标
Open Forum Infect Dis. 2019 Nov 3;6(12):ofz485. doi: 10.1093/ofid/ofz485. eCollection 2019 Dec.
5
Crowdsourcing contests to facilitate community engagement in HIV cure research: a qualitative evaluation of facilitators and barriers of participation.众包竞赛以促进社区参与 HIV 治愈研究：对参与的促进因素和障碍的定性评估。
BMC Public Health. 2020 Jan 15;20(1):67. doi: 10.1186/s12889-020-8185-z.
6
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).治疗性疫苗使早期接受治疗的个体的T细胞反应重新聚焦于HIV-1的保守区域（BCN 01研究）。
EClinicalMedicine. 2019 Jun 5;11:65-80. doi: 10.1016/j.eclinm.2019.05.009. eCollection 2019 May-Jun.
7
Perceptions of HIV cure research among people living with HIV in Australia.澳大利亚 HIV 感染者对 HIV 治愈研究的看法。
PLoS One. 2018 Aug 24;13(8):e0202647. doi: 10.1371/journal.pone.0202647. eCollection 2018.
8
Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.金黄色葡萄球菌 Cas9 对 CXCR4 的基因组修饰使细胞对 HIV-1 感染具有抗性。
Retrovirology. 2017 Nov 15;14(1):51. doi: 10.1186/s12977-017-0375-0.
9
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.接种MVA-B疫苗的HIV-1感染受试者治疗中断后的病毒学和免疫学结果。
PLoS One. 2017 Sep 27;12(9):e0184929. doi: 10.1371/journal.pone.0184929. eCollection 2017.
10
The latest science from the IAS Towards an HIV Cure Symposium: 16-17 July 2016, Durban, South Africa.来自国际艾滋病学会“迈向治愈艾滋病”研讨会的最新科学成果：2016年7月16 - 17日，南非德班
J Virus Erad. 2016 Oct 5;2(4):235-241. doi: 10.1016/S2055-6640(20)30877-3.
本文引用的文献
1
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.泊马度胺，一种组蛋白去乙酰化酶抑制剂，用于抑制性抗逆转录病毒治疗的 HIV 感染患者潜伏病毒的再激活：一项 1/2 期、单组、临床试验。
Lancet HIV. 2014 Oct;1(1):e13-21. doi: 10.1016/S2352-3018(14)70014-1. Epub 2014 Sep 15.
2
Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV.慢性病毒感染控制中活化自然杀伤细胞受体的基线和动态表达：以HIV-1和HCV为例
Front Immunol. 2014 Jul 2;5:305. doi: 10.3389/fimmu.2014.00305. eCollection 2014.
3
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.异基因干细胞移植后无抗逆转录病毒治疗的HIV-1缓解及病毒反弹：2例报告
Ann Intern Med. 2014 Sep 2;161(5):319-27. doi: 10.7326/M14-1027.
4
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.恒河猴体内SIV病毒血症出现之前病毒储存库的快速播种。
Nature. 2014 Aug 7;512(7512):74-7. doi: 10.1038/nature13594. Epub 2014 Jul 20.
5
An HIV cure: feasibility, discovery, and implementation.治愈人类免疫缺陷病毒：可行性、发现与实施
JAMA. 2014;312(4):335-6. doi: 10.1001/jama.2014.4754.
6
Immunologic strategies for HIV-1 remission and eradication.HIV-1 缓解和清除的免疫策略。
Science. 2014 Jul 11;345(6193):169-74. doi: 10.1126/science.1255512.
7
A critical question for HIV vaccine development: which antibodies to induce?HIV 疫苗研发的一个关键问题：诱导产生哪些抗体？
Science. 2014 Jul 11;345(6193):167-8. doi: 10.1126/science.1256526.
8
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.针对HIV-1包膜的中和抗体在体内的保护作用比针对CD4受体的中和抗体更有效。
Sci Transl Med. 2014 Jul 2;6(243):243ra88. doi: 10.1126/scitranslmed.3008992.
9
Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.广谱中和抗体VRC01可防止HIV-1从浆细胞样树突状细胞传播至CD4 T淋巴细胞。
J Virol. 2014 Sep;88(18):10975-81. doi: 10.1128/JVI.01748-14. Epub 2014 Jun 25.
10
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.来自麻风树的新型大戟醇衍生物在HIV复制中的双重作用：抑制从头感染和激活病毒长末端重复序列
PLoS One. 2014 May 14;9(5):e97257. doi: 10.1371/journal.pone.0097257. eCollection 2014.
Zotero 插件